Chimeric Therapeutics CEO Dr Rebecca McQualter talked with Proactive's Stephen Gunnion about the progress of the company's clinical trials, focusing on its leading asset, CHM CDH17, a third-generation CAR T-cell therapy targeting gastrointestinal cancers, neuroendocrine tumours, and colorectal cancers. McQualter highlighted that Chimeric Therapeutics has dosed three patients and completed five successful manufacturing runs for CHM CDH17, emphasising the excitement around the program's progress. The therapy, developed from technology licensed from the University of Pennsylvania (UPenn), aims to address a significant gap in treatments for patients with cancers along the gastrointestinal tract. The Phase 1/2 trial is currently in the dose-escalation stage, with a design that tests increasing cell doses to find the optimal therapeutic level. "We should have some really great news coming ahead," McQualter said, referencing anticipated results from both the initial and subsequent cohorts of patients. In addition to clinical advancements, Chimeric Therapeutics reported a solid financial position following a A$5 million placement and a A$4 million tax incentive, which supports the company’s ongoing trials. Stay tuned to Proactive's YouTube channel for more insightful interviews and updates. Don’t forget to like the video, subscribe to our channel, and turn on notifications for future content! #ChimericTherapeutics #Biotech #CellTherapy #CancerTreatment #CHMCDH17 #ClinicalTrials #CAR-TCell #GastrointestinalCancer #InvestorNews #ProactiveInvestors